
Lam Research Corporation (LRCX), a large-cap semiconductor growth stock, received an 86% rating from Validea's Warren Buffett-inspired "Patient Investor" model. This high score, indicating significant interest, reflects LRCX's strong underlying fundamentals, including predictable profitability, low debt, and robust free cash flow, aligning with the model's criteria for long-term value, despite a noted 'Fail' in Return on Total Capital.
Lam Research Corporation (LRCX) screens favorably under Validea's "Patient Investor" model, which is based on Warren Buffett's principles, achieving a high score of 86%. This score indicates significant alignment with the model's criteria for long-term investment, which favor predictable profitability, low debt, and reasonable valuations. The analysis highlights LRCX's strengths in several key fundamental areas, as it passed tests for earnings predictability, debt service, return on equity, and free cash flow generation. Furthermore, the company's positive ratings for its use of retained earnings and share repurchase programs suggest efficient capital allocation and a shareholder-friendly approach. The single point of weakness identified by the model is the company's 'Fail' on the Return on Total Capital metric, which suggests that while returns on equity are strong, the efficiency of returns generated from the company's complete capital base (debt plus equity) may warrant further scrutiny.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment